Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

North Ryde, Australia Clinical Trials

A listing of North Ryde, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (67) clinical trials

A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's

The study is designed as a multicentre, phase 1b open-label study. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with mild to moderate Alzheimer's disease and elevated blood levels of the inflammatory biomarker high sensitivity c-reactive protein (hs-CRP). XPro1595 is a …

Phase

0.86 miles

Learn More »

A Study of ZN-c5 in Participants With Breast Cancer

This is a Phase 1 open-label, multicenter study to evaluate biomarkers for ZN-c5 in subjects with breast cancer

Phase

1.34 miles

Learn More »

A Study Evaluating the Safety Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

This is a study to evaluate the safety and tolerability of the study drug HBM4003, and to determine the maximum tolerated dose and/or recommended Phase 2 study dose of HBM4003. Participants will receive 3 escalating doses of HBM4003, with the possibility of a fourth, higher dose level following review by …

Phase

1.34 miles

Learn More »

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06804103 in patients with HER2 positive and negative breast and gastric cancer (HER2 positive only and gastric were studied in Part 1A only). The study will expand to look at selected doses in patients with HER2 positive …

Phase

1.34 miles

Learn More »

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

In the dose escalation phase, the following will be assessed: Arm A: escalating doses of etrumadenant in combination with PLD at standard doses will be assessed in participants with advanced metastatic triple-negative breast cancer or ovarian cancer. Eligible participants will receive oral administration of etrumadenant as well as intravenous (IV) …

Phase

1.34 miles

Learn More »

A Study of IMU-201 (PD1-Vaxx) a B-Cell Immunotherapy in Adults With Non-Small Cell Lung Cancer

Investigational Medicinal Product, IMU-201, consists of drug substance, APi2568, which is a B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T-cell epitope (amino acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker (Gly-Pro-Ser-Leu), and combined with Water for Injection (WFI) forms the drug …

Phase

1.34 miles

Learn More »

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with …

Phase

3.48 miles

Learn More »

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation …

Phase

4.38 miles

Learn More »

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Subjects can only be enrolled in one treatment arm. The probes (which are given twice) used in the study are approved for use in the countries where the study will be conducted. The probes in Arm 1 consist of single doses of caffeine (100mg), dextromethorphan (30 mg), flurbiprofen (50 mg), …

Phase

4.38 miles

Learn More »

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Na ve Higher-Risk Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-nave higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Phase

4.77 miles

Learn More »